110 related articles for article (PubMed ID: 19577536)
1. Restoration of cyclin D2 has an inhibitory potential on the proliferation of LNCaP cells.
Kobayashi T; Nakamura E; Shimizu Y; Terada N; Maeno A; Kobori G; Kamba T; Kamoto T; Ogawa O; Inoue T
Biochem Biophys Res Commun; 2009 Sep; 387(1):196-201. PubMed ID: 19577536
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor-dependent and -independent mechanisms mediate Ganoderma lucidum activities in LNCaP prostate cancer cells.
Zaidman BZ; Wasser SP; Nevo E; Mahajna J
Int J Oncol; 2007 Oct; 31(4):959-67. PubMed ID: 17786330
[TBL] [Abstract][Full Text] [Related]
5. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M
Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155
[TBL] [Abstract][Full Text] [Related]
6. Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells.
Hsieh CL; Cai C; Giwa A; Bivins A; Chen SY; Sabry D; Govardhan K; Shemshedini L
J Mol Endocrinol; 2008 Jul; 41(1):13-23. PubMed ID: 18469090
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
8. Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.
Liu CM; Lo YC; Tai MH; Wu BN; Wu WJ; Chou YH; Chai CY; Huang CH; Chen IJ
Prostate; 2009 May; 69(6):610-23. PubMed ID: 19143029
[TBL] [Abstract][Full Text] [Related]
9. Nkx3.1 and p27(KIP1) cooperate in proliferation inhibition and apoptosis induction in human androgen-independent prostate cancer cells.
Wang P; Ma Q; Luo J; Liu B; Tan F; Zhang Z; Chen Z
Cancer Invest; 2009 May; 27(4):369-75. PubMed ID: 19266349
[TBL] [Abstract][Full Text] [Related]
10. Expression, regulation and function of the ISGylation system in prostate cancer.
Kiessling A; Hogrefe C; Erb S; Bobach C; Fuessel S; Wessjohann L; Seliger B
Oncogene; 2009 Jul; 28(28):2606-20. PubMed ID: 19430494
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of cyclin D2 is associated with increased in vivo invasiveness of human squamous carcinoma cells.
Liu SC; Bassi DE; Zhang SY; Holoran D; Conti CJ; Klein-Szanto AJ
Mol Carcinog; 2002 Jul; 34(3):131-9. PubMed ID: 12112307
[TBL] [Abstract][Full Text] [Related]
12. Identification of mu-crystallin as an androgen-regulated gene in human prostate cancer.
Malinowska K; Cavarretta IT; Susani M; Wrulich OA; Uberall F; Kenner L; Culig Z
Prostate; 2009 Jul; 69(10):1109-18. PubMed ID: 19353593
[TBL] [Abstract][Full Text] [Related]
13. [The effect of cyclin D2 shRNA on the proliferation and apoptosis of LP-1 cell].
Guo C; Hou J; Chen YB; Jin HY; Fu WJ; Yuan ZG; Wang DX
Zhonghua Xue Ye Xue Za Zhi; 2006 Oct; 27(10):666-9. PubMed ID: 17343197
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines.
Pignon JC; Koopmansch B; Nolens G; Delacroix L; Waltregny D; Winkler R
Cancer Res; 2009 Apr; 69(7):2941-9. PubMed ID: 19318561
[TBL] [Abstract][Full Text] [Related]
15. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors.
Snoek R; Cheng H; Margiotti K; Wafa LA; Wong CA; Wong EC; Fazli L; Nelson CC; Gleave ME; Rennie PS
Clin Cancer Res; 2009 Jan; 15(1):39-47. PubMed ID: 19118031
[TBL] [Abstract][Full Text] [Related]
16. Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth.
Takayama K; Tsutsumi S; Suzuki T; Horie-Inoue K; Ikeda K; Kaneshiro K; Fujimura T; Kumagai J; Urano T; Sakaki Y; Shirahige K; Sasano H; Takahashi S; Kitamura T; Ouchi Y; Aburatani H; Inoue S
Cancer Res; 2009 Jan; 69(1):137-42. PubMed ID: 19117996
[TBL] [Abstract][Full Text] [Related]
17. Pleiotropic functional properties of androgen receptor mutants in prostate cancer.
Bergerat JP; Céraline J
Hum Mutat; 2009 Feb; 30(2):145-57. PubMed ID: 18800375
[TBL] [Abstract][Full Text] [Related]
18. Deregulation of cyclin D2 by juxtaposition with T-cell receptor alpha/delta locus in t(12;14)(p13;q11)-positive childhood T-cell acute lymphoblastic leukemia.
Karrman K; Andersson A; Björgvinsdóttir H; Strömbeck B; Lassen C; Olofsson T; Nguyen-Khac F; Berger R; Bernard O; Fioretos T; Johansson B
Eur J Haematol; 2006 Jul; 77(1):27-34. PubMed ID: 16548914
[TBL] [Abstract][Full Text] [Related]
19. Conversion of prostate cancer from hormone independency to dependency due to AMACR inhibition: involvement of increased AR expression and decreased IGF1 expression.
Takahara K; Azuma H; Sakamoto T; Kiyama S; Inamoto T; Ibuki N; Nishida T; Nomi H; Ubai T; Segawa N; Katsuoka Y
Anticancer Res; 2009 Jul; 29(7):2497-505. PubMed ID: 19596919
[TBL] [Abstract][Full Text] [Related]
20. Cell cycle regulator cdk2ap1 inhibits prostate cancer cell growth and modifies androgen-responsive pathway function.
Zolochevska O; Figueiredo ML
Prostate; 2009 Oct; 69(14):1586-97. PubMed ID: 19585490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]